Comparing AquaBounty Technologies (AQB) and Its Competitors

AquaBounty Technologies (NASDAQ:AQB) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare AquaBounty Technologies to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for AquaBounty Technologies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1	0	0	0	1.00
AquaBounty Technologies Competitors	9869	15284	45615	1598	2.54

As a group, “Biotechnology” companies have a potential upside of 125.34%. Given AquaBounty Technologies’ rivals stronger consensus rating and higher possible upside, analysts clearly believe AquaBounty Technologies has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares AquaBounty Technologies and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AquaBounty Technologies	$2.47 million	-$18.49 million	-1.23
AquaBounty Technologies Competitors	$700.54 million	$9.44 million	-18.96

AquaBounty Technologies’ rivals have higher revenue and earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares AquaBounty Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-43.18%
AquaBounty Technologies Competitors	-12,323.33%	-195.91%	-30.60%

Insider & Institutional Ownership

8.9% of AquaBounty Technologies shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.0% of AquaBounty Technologies shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

AquaBounty Technologies has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, AquaBounty Technologies’ rivals have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Summary

AquaBounty Technologies rivals beat AquaBounty Technologies on 9 of the 12 factors compared.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc. is a biotechnology and aquaculture company focused on developing and producing land-raised Atlantic salmon. Its principal product is AquAdvantage salmon, a genetically engineered salmon designed to reach market size more quickly than conventional Atlantic salmon. The company has pursued land-based, contained aquaculture systems intended to reduce reliance on ocean-based farming and improve production efficiency. AquAdvantage salmon incorporates a growth-hormone gene from Chinook salmon and a regulatory sequence from ocean pout.